Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT06962163
Prospective Phase 0 Pilot Study, Assessing Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients
Overview
The goal of the study is to assess how [68Ga]Ga-PentixaFor is distributed in the body using PET/CT imaging. This will help demonstrate the potential of CXCR4 as a promising target for new treatments. If successful, [68Ga]Ga-PentixaFor PET/CT could become a valuable tool for identifying patients who might benefit from treatments using [177Lu]/[90Y] PentixaTher.
Sponsor
Institut Cancerologie de l'Ouest
Phase
N/A
Contacts
CAROLINE ROUSSEAU, MD, PhD
caroline.rousseau@ico.unicancer.fr
+33 2 40 67 99 31
NADIA ALLAM, PhD
nadia.allam@ico.unicancer.fr
+33 2 40 67 98 26
ClinicalTrials.gov
NCT06962163Drug / Compound
[68Ga]Ga-Pentixafor
Isotope(s):
GALLIUM-68
Radioisotope: Ga-68
Theranostic Role: PET Imaging
T1/2 (Half-Life): 68 minutes
Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
Range: N/A
Decay Daughters: Zn68 (Stable)
Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
Target(s):
- CXCR4
Ligand Class: Small Molecules
Chelator: DOTA
Share your feedback
Help us improve your experience